SG11202110524VA - Compounds and conjugates thereof - Google Patents

Compounds and conjugates thereof

Info

Publication number
SG11202110524VA
SG11202110524VA SG11202110524VA SG11202110524VA SG11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA SG 11202110524V A SG11202110524V A SG 11202110524VA
Authority
SG
Singapore
Prior art keywords
conjugates
compounds
Prior art date
Application number
SG11202110524VA
Inventor
Philip Howard
Niall Dickinson
Thais Cailleau
Luke Masterson
William Goundry
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69960637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202110524V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11202110524VA publication Critical patent/SG11202110524VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
SG11202110524VA 2019-03-29 2020-03-23 Compounds and conjugates thereof SG11202110524VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826393P 2019-03-29 2019-03-29
US202062964177P 2020-01-22 2020-01-22
PCT/EP2020/057984 WO2020200880A1 (en) 2019-03-29 2020-03-23 Compounds and conjugates thereof

Publications (1)

Publication Number Publication Date
SG11202110524VA true SG11202110524VA (en) 2021-10-28

Family

ID=69960637

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110524VA SG11202110524VA (en) 2019-03-29 2020-03-23 Compounds and conjugates thereof

Country Status (26)

Country Link
US (3) US20220211863A1 (en)
EP (2) EP4176904A1 (en)
JP (2) JP7210770B2 (en)
KR (2) KR20230023814A (en)
CN (2) CN117263948A (en)
AU (1) AU2020252034B2 (en)
BR (1) BR112021018986A2 (en)
CA (1) CA3133757A1 (en)
CL (1) CL2021002498A1 (en)
CO (1) CO2021014566A2 (en)
CR (1) CR20210541A (en)
DK (1) DK3946464T3 (en)
EC (1) ECSP21078204A (en)
ES (1) ES2930295T3 (en)
HR (1) HRP20221280T1 (en)
HU (1) HUE060364T2 (en)
IL (1) IL286291A (en)
LT (1) LT3946464T (en)
MX (1) MX2021011812A (en)
PL (1) PL3946464T3 (en)
PT (1) PT3946464T (en)
RS (1) RS63715B1 (en)
SG (1) SG11202110524VA (en)
TW (1) TWI826676B (en)
WO (1) WO2020200880A1 (en)
ZA (1) ZA202106612B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11493668B2 (en) 2018-09-26 2022-11-08 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
WO2020200880A1 (en) * 2019-03-29 2020-10-08 Medimmune Limited Compounds and conjugates thereof
KR20220051332A (en) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. Peptide Conjugates of Microtubule Targeting Agents as Therapeutic Agents
CN114341162A (en) 2019-07-10 2022-04-12 赛博克萨2公司 Peptide conjugates of cytotoxins as therapeutic agents
KR20220130749A (en) * 2020-01-22 2022-09-27 메디뮨 리미티드 Compounds and conjugates thereof
TW202140076A (en) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 Compounds and conjugates thereof
WO2023020531A1 (en) 2021-08-17 2023-02-23 江苏迈威康新药研发有限公司 Method for synthesizing 5,8-diamino-3,4-dihydro-2h-1-naphthalenone and intermediate compound used therein
CN116813631A (en) * 2021-12-16 2023-09-29 迈威(上海)生物科技股份有限公司 Camptothecins compound and conjugate thereof
TW202348252A (en) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 Combination therapies for treatment of cancer with therapeutic binding molecules
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023180490A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023180484A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing ptk7
WO2023180489A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
WO2023180485A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
CN115160403A (en) * 2022-07-05 2022-10-11 上海彩迩文生化科技有限公司 Specific topoisomerase inhibitor and conjugate used for antibody drug and preparation method thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
JP2754022B2 (en) * 1988-11-18 1998-05-20 第一製薬株式会社 Camptothecin analogs
JP3024013B2 (en) * 1990-08-14 2000-03-21 杏林製薬株式会社 Fluoroethyl camptothecin derivative
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3008226B2 (en) 1991-01-16 2000-02-14 第一製薬株式会社 Hexacyclic compounds
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3359955B2 (en) * 1992-07-16 2002-12-24 第一製薬株式会社 Antitumor agent
EA000122B1 (en) 1995-02-22 1998-08-27 Дайити Фармасьютикал Ко., Лтд. Aminotetralone derivatives and process for producing the same
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JPH1095802A (en) * 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd Camptothecine derivative
IN189180B (en) 1997-07-09 2003-01-04 Chong Kun Dang Corp
AR030207A1 (en) 2000-04-07 2003-08-13 Daiichi Seiyaku Co PHARMACEUTICAL COMPOSITION CONTAINING A CAMPTOTECHINE DERIVATIVE AND PREPARATION PROCEDURE OF THE SAME
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6737548B2 (en) 2001-05-08 2004-05-18 Mitsui Chemicals, Inc. Process for preparing 1,5-diaminonaphthalene derivative
RU2299212C2 (en) 2001-11-30 2007-05-20 Чугаи Сейяку Кабусики Кайся Hexacyclic compounds, pharmaceutical composition containing thereof and their using as antitumor agents, method for preparing hexacyclic compounds
WO2004073601A2 (en) 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
BRPI0509732A (en) 2004-04-09 2007-09-25 Chugai Pharmaceutical Co Ltd water soluble prodrug, pharmaceutical composition, therapeutic agent, antifungal agent and use of said prodrug
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EA032466B1 (en) 2005-10-07 2019-05-31 Экселиксис, Инк. Methods of making mek inhibitors
SI1813614T1 (en) 2006-01-25 2012-01-31 Sanofi 174 Cytotoxic agents comprising new tomaymycin derivatives
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
JP5769616B2 (en) 2008-04-30 2015-08-26 イミュノジェン・インコーポレーテッド Crosslinkers and their use
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
CN102850400A (en) * 2011-06-30 2013-01-02 周文强 Camptothecin derivative, and preparation method, pharmaceutical composition and use thereof
EP3632471A1 (en) 2012-10-11 2020-04-08 Daiichi Sankyo Company, Limited Antibody-drug conjugate
JP6272230B2 (en) 2012-10-19 2018-01-31 第一三共株式会社 Antibody-drug conjugate conjugated with a linker containing a hydrophilic structure
US9962452B2 (en) 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
CN105744935B (en) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 Hydrazino-pyrrolo compounds and methods for forming conjugates
SI3088419T1 (en) 2013-12-25 2019-01-31 Daiichi Sankyo Company Anti-trop2 antibody-drug conjugate
KR20230162159A (en) 2014-01-31 2023-11-28 다이이찌 산쿄 가부시키가이샤 Anti-her2 antibody-drug conjugate
JP2017114763A (en) 2014-03-26 2017-06-29 第一三共株式会社 Anti-CD98 antibody-drug conjugate
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
IL300540B1 (en) 2014-04-10 2024-04-01 Daiichi Sankyo Co Ltd Method for producing an anti-her3 antibody-drug conjugate
JP6733993B2 (en) 2014-10-03 2020-08-05 シンアフィックス ビー．ブイ． Sulfamide linker, conjugate of sulfamide linker, and method of preparation
HUE055644T2 (en) 2015-01-30 2022-03-28 Sutro Biopharma Inc Hemiasterlin derivatives for conjugation and therapy
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CN116059395A (en) 2015-06-29 2023-05-05 第一三共株式会社 Method for selectively producing antibody-drug conjugates
MA43354A (en) * 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
AU2017341000A1 (en) 2016-10-07 2019-04-11 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate
SG11201903771XA (en) 2016-11-10 2019-05-30 Medimmune Llc Binding molecules specific for asct2 and uses thereof
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (en) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd antibody or antibody functional fragment, polynucleotide, expression vector, host cells, method for producing an antibody of interest or antibody functional fragment and for producing an antibody-drug conjugate, antibody-drug conjugate, pharmaceutical composition , antitumor drug; and, method of treating a tumor.
SG11201907050PA (en) 2017-02-28 2019-09-27 Univ Kinki Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
TW202330036A (en) 2017-05-15 2023-08-01 日商第一三共股份有限公司 Manufacturing method of antibody-drug conjugates
CN108853514B (en) 2017-08-18 2022-07-22 四川百利药业有限责任公司 Antibody drug conjugates with two different drugs
WO2019034176A1 (en) 2017-08-18 2019-02-21 四川百利药业有限责任公司 Camptothecin-antibody conjugate
WO2020200880A1 (en) * 2019-03-29 2020-10-08 Medimmune Limited Compounds and conjugates thereof

Also Published As

Publication number Publication date
EP4176904A1 (en) 2023-05-10
US20220211863A1 (en) 2022-07-07
CN113631196B (en) 2024-03-15
JP7210770B2 (en) 2023-01-23
KR20230023814A (en) 2023-02-17
IL286291A (en) 2021-10-31
TWI826676B (en) 2023-12-21
ES2930295T3 (en) 2022-12-09
LT3946464T (en) 2022-11-10
JP2022528851A (en) 2022-06-16
CO2021014566A2 (en) 2021-11-19
AU2020252034B2 (en) 2024-02-01
BR112021018986A2 (en) 2022-01-18
KR102498681B1 (en) 2023-02-09
CL2021002498A1 (en) 2022-06-03
ECSP21078204A (en) 2021-11-30
HRP20221280T1 (en) 2022-12-23
CR20210541A (en) 2021-12-20
CA3133757A1 (en) 2020-10-08
PT3946464T (en) 2022-11-16
DK3946464T3 (en) 2022-10-31
RS63715B1 (en) 2022-11-30
CN113631196A (en) 2021-11-09
AU2020252034A1 (en) 2021-11-11
US20200306243A1 (en) 2020-10-01
KR20210144845A (en) 2021-11-30
WO2020200880A1 (en) 2020-10-08
HUE060364T2 (en) 2023-02-28
TW202104235A (en) 2021-02-01
PL3946464T3 (en) 2022-12-19
JP2023065346A (en) 2023-05-12
EP3946464B1 (en) 2022-08-31
US20210322401A1 (en) 2021-10-21
ZA202106612B (en) 2022-08-31
US11446292B2 (en) 2022-09-20
EP3946464A1 (en) 2022-02-09
MX2021011812A (en) 2021-10-22
CN117263948A (en) 2023-12-22

Similar Documents

Publication Publication Date Title
IL286291A (en) Compounds and conjugates thereof
IL285178A (en) Compounds and uses thereof
IL278877B1 (en) Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
IL286847A (en) Hsp90-binding conjugates and formulations thereof
IL285177A (en) Compounds and uses thereof
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
ZA202105752B (en) Haloallylamine compounds and application thereof
IL277791A (en) Hsp90-targeting conjugates and formulations thereof
IL291499A (en) Aza-quinoline compounds and uses thereof
IL286497A (en) Compounds and uses thereof
IL284764A (en) Compounds and uses thereof
GB201820626D0 (en) Conjugates
IL285118A (en) Compounds and uses thereof
GB201820864D0 (en) Antibody-drug conjugates
GB201903535D0 (en) Compounds and conjugates
GB201903541D0 (en) Compounds and conjugates
IL288681A (en) Pyrrolobenzodiazepine-antibody conjugates
GB201906997D0 (en) Conjugates
GB201900735D0 (en) Conjugates
ZA202201239B (en) Aminothiolester compounds and uses thereof
GB202000121D0 (en) Compounds and conjugates
GB201811332D0 (en) Pyrroloobenzodiazepine-antibody conjugates
GB201811335D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201908126D0 (en) Pyrrolobenzodiazepine conjugates
GB201905117D0 (en) Pyrrolobenzodiazepine conjugates